Jade Biosciences, Inc.
JBIO
$12.00
$0.383.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 5.39M | 5.23M | 3.36M | 1.90M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 27.40M | 27.78M | 23.38M | 15.56M | |
| Operating Income | -27.40M | -27.78M | -23.38M | -15.56M | |
| Income Before Tax | -25.18M | -32.13M | -38.17M | -16.87M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -25.18M | -32.13M | -38.17M | -16.87M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -25.18M | -32.13M | -38.17M | -16.87M | |
| EBIT | -27.40M | -27.78M | -23.38M | -15.56M | |
| EBITDA | -27.39M | -27.78M | -- | -- | |
| EPS Basic | -0.48 | -0.86 | -8.86 | -5.35 | |
| Normalized Basic EPS | -0.40 | -0.57 | -4.14 | -3.00 | |
| EPS Diluted | -0.48 | -0.86 | -8.86 | -5.35 | |
| Normalized Diluted EPS | -0.40 | -0.57 | -4.14 | -3.00 | |
| Average Basic Shares Outstanding | 39.58M | 28.43M | 3.43M | 3.16M | |
| Average Diluted Shares Outstanding | 39.58M | 28.43M | 3.43M | 3.16M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |